Last reviewed · How we verify
CPX-351 in cohort A
At a glance
| Generic name | CPX-351 in cohort A |
|---|---|
| Sponsor | Groupe Francophone des Myelodysplasies |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CPX-351 in cohort A CI brief — competitive landscape report
- CPX-351 in cohort A updates RSS · CI watch RSS
- Groupe Francophone des Myelodysplasies portfolio CI